Ray Dalio's CRL Position Overview
Ray Dalio (via Bridgewater Associates, Lp) currently holds 19,908 shares of Charles River Laboratories International, Inc. (CRL) worth $3.11 M, representing 0.01% of the portfolio. First purchased in 2014-Q3, this long-term strategic position has been held for 45 quarters.
Based on 13F filings since 2013, Ray Dalio has maintained a long-term strategic position in CRL, representing a significant commitment to this investment thesis. Largest addition occurred in Q3 2025, adding 18,808 shares. Largest reduction occurred in Q4 2015, reducing 17,000 shares.
Analysis based on 13F filings available since 2013 Q2
Ray Dalio's Charles River Laboratories International (CRL) Holding Value Over Time
Track share changes against reported price movement
Quarterly Charles River Laboratories International (CRL) Trades by Ray Dalio
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q3 2014 | +4,200 | New Buy | 4,200 | $59.76 |
| Q4 2014 | +1,000 | Add 23.81% | 5,200 | $63.65 |
| Q1 2015 | -500 | Reduce 9.62% | 4,700 | $79.36 |
| Q2 2015 | -4,700 | Sold Out | 4,700 | $0.00 |
| Q3 2015 | +19,687 | New Buy | 19,687 | $63.54 |
| Q4 2015 | -17,000 | Reduce 86.35% | 2,687 | $80.39 |
| Q1 2016 | -2,687 | Sold Out | 2,687 | $0.00 |
| Q2 2017 | +6,709 | New Buy | 6,709 | $101.21 |
| Q3 2017 | -4,135 | Reduce 61.63% | 2,574 | $108.00 |
| Q4 2017 | -2,574 | Sold Out | 2,574 | $0.00 |
| Q1 2018 | +12,245 | New Buy | 12,245 | $106.74 |
| Q2 2018 | -1,740 | Reduce 14.21% | 10,505 | $112.23 |
| Q3 2018 | -7,459 | Reduce 71.00% | 3,046 | $134.60 |
| Q4 2018 | +12,120 | Add 397.90% | 15,166 | $113.15 |
| Q1 2019 | -15,166 | Sold Out | 15,166 | $0.00 |
| Q3 2019 | +3,406 | New Buy | 3,406 | $132.41 |
| Q4 2019 | -3,406 | Sold Out | 3,406 | $0.00 |
| Q3 2021 | +649 | New Buy | 649 | $412.94 |
| Q4 2021 | +838 | Add 129.12% | 1,487 | $376.60 |
| Q1 2022 | +3,453 | Add 232.21% | 4,940 | $284.01 |
| Q2 2022 | +666 | Add 13.48% | 5,606 | $214.06 |
| Q3 2022 | -3,553 | Reduce 63.38% | 2,053 | $196.79 |
| Q4 2022 | +1,392 | Add 67.80% | 3,445 | $217.90 |
| Q1 2023 | -263 | Reduce 7.63% | 3,182 | $201.82 |
| Q2 2023 | +1,124 | Add 35.32% | 4,306 | $210.25 |
| Q3 2023 | -1,301 | Reduce 30.21% | 3,005 | $195.98 |
| Q4 2023 | -240 | Reduce 7.99% | 2,765 | $236.40 |
| Q1 2024 | -1,665 | Reduce 60.22% | 1,100 | $270.95 |
| Q2 2024 | -1,100 | Sold Out | 1,100 | $0.00 |
| Q3 2025 | +19,908 | New Buy | 19,908 | $156.46 |
Ray Dalio's Charles River Laboratories International Investment FAQs
Ray Dalio first purchased Charles River Laboratories International, Inc. (CRL) in Q3 2014, acquiring 4,200 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ray Dalio has held Charles River Laboratories International, Inc. (CRL) for 45 quarters since Q3 2014. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ray Dalio's largest addition to Charles River Laboratories International, Inc. (CRL) was in Q3 2025, adding 19,908 shares worth $3.11 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Ray Dalio's firm, Bridgewater Associates, Lp, owns 19,908 shares of Charles River Laboratories International, Inc. (CRL), valued at approximately $3.11 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, Charles River Laboratories International, Inc. (CRL) represents approximately 0.01% of Ray Dalio's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ray Dalio's peak holding in Charles River Laboratories International, Inc. (CRL) was 19,908 shares, as reported at the end of Q3 2025. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.